Advanced Glycosylation End-Products in Diabetic Rats on Peritoneal Dialysis Using Various Solutions

Abstract

Objective

To evaluate and compare the effects of glucose-based solutions to those of icodextrin with respect to peritoneal transport characteristics and advanced glycosylation end-product (AGE) formation in the peritoneal membrane in a diabetic rat model of peritoneal dialysis (PD).

Design

Thirty-three male Sprague–Dawley rats weighing between 275 – 300 g were divided into five groups: group C (n = 6), control rats implanted with a catheter but not dialyzed; group D (n = 5), diabetic rats implanted with a catheter but not dialyzed; group G (n = 7), diabetic rats implanted with a catheter and dialyzed with standard 2.5% glucose solution for daytime exchanges and 4.25% glucose solution for overnight exchanges; group H (n = 8), diabetic rats implanted with a catheter and dialyzed with standard 2.5% glucose solution for daytime exchanges and 7.5% icodextrin solution for overnight exchanges; group I (n = 7), diabetic rats implanted with a catheter and dialyzed with 7.5% icodextrin solution for all exchanges. Dialysis exchanges (25 mL per exchange) were performed three times daily for a period of 12 weeks. Tissue sections were stained using a monoclonal anti-AGE antibody. One-hour peritoneal equilibration tests (PET) were performed every 4 weeks for comparison of transport characteristics.

Results

The level of immunostaining was lowest in group C and highest in group G. Significant differences in immunostaining were seen between group C and group G (p < 0.001), group C and group H (p = 0.001), and group C and group I (p < 0.05). Significant differences were also found between group G and group D (p < 0.05), and between group G and group I (p < 0.05). Over time, the ratio of glucose concentration after 1 hour to glucose concentration at instillation (D/D₀) decreased and the dialysate-to-plasma ratio (D/P) of urea increased. Significant differences in D/D₀ glucose and D/P urea were found between group C and group H (D/D₀: 0.40 ± 0.01 vs 0.35 ± 0.01, p < 0.05; D/P urea: 0.87 ± 0.03 vs 0.97 ± 0.02, p < 0.05).

Conclusions

These results suggest that AGE formation is lower with the use of peritoneal dialysis solution containing icodextrin than with glucose-based solution. We conclude that use of icodextrin may help to slow the deterioration of the peritoneal membrane, prolonging its use for dialysis.

Keywords

Glycosylation advanced glycosylation end-products icodextrin dialysis solutions

Get full access to this article

View all access options for this article.

References

Feriani

, LaGreca

, Kriger

F.L.

, Winchester

J.F.

CAPD systems and solutions. In: Gokal

, Nolph

K.D.

, eds. The textbook of peritoneal dialysis. London: Kluwer Academic Publishers; 1994: 233–70.

Honda

, Nitta

, Horita

, Yumura

, Nihei

Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure.

Nephron 1996; 72: 171–6.

de Fijter

C.W.H.

, Oe

P.L.

, Donker

A.J.M.

, Verhoef

, Verbrugh

H.A.

Compatibility of peritoneal dialysis fluids containing alternative osmotic agents with cells present in the peritoneal cavity.

Perit Dial Int 1994; 14(Suppl 2): S33–8.

Hain

, Kessel

Aspects of new solutions for peritoneal dialysis.

Nephrol Dial Transplant 1987; 2: 67–72.

Dobbie

, Lloyd

J.K.

, Gall

C.A.

Categorization of the ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients.

Adv Perit Dial 1990; 6: 3–12.

Davies

D.S.

Kinetics of icodextrin.

Perit Dial Int 1994; 14(Suppl 2): S45–50.

Mistry

C.D.

, Gokal

, Peers

E.M.

, and the MIDAS study group. A randomized multicenter clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solution in CAPD. Kidney Int 1994; 46: 496–503.

Posthuma

, ter Wee

P.M.

, Donker

A.J.M.

, Oe

L.P.

, Verbrugh

H.A.

, Peers

Improved ultrafiltration in CCPD patients using icodextrin (I) instead glucose (G) during the long daytime dwell (Abstract).

J Am Soc Nephrol 1995; 6: 513, Abstract 406.

Krediet

R.T.

, Ho-dac-Pannekeet

M.M.

, Imholz

A.L.

, Struijk

D.G.

Icodextrin's effects on peritoneal transport.

Perit Dial Int 1997; 17: 35–41.

10.

Dawnay

A.B.S.

, Millar

D.J.

Glycation and advanced glycation end-product formation with icodextrin and dextrose.

Perit Dial Int 1997; 17: 52–8.

11.

Bucala

, Vlassara

, Cerami

Advanced glycosylation end-products. In: Harding

J.J.

, Crabbe

M.J.C.

, eds. Post-translational modifications of proteins. Boca Raton: CRC Press; 1992: 53–79.

12.

Eble

A.S.

, Thorpe

S.R.

, Baynes

J.W.

Nonenzymatic glycosylation and glucose-dependent cross-linking protein.

J Biol Chem 1983; 258: 9406–12.

13.

Wells–Knecht

K.J.

, Lyons

T.J.

, McCance

D.R.

, Thorpe

S.R.

, Feather

M.S.

, Baynes

J.W.

3-Deoxyfructose concentrations are increased in human plasma and urine in diabetes.

Diabetes 1994; 443: 1152–6.

14.

Yamada

, Miyata

, Igaki

, Yatabe

, Miyauchi

, Ohara

Increase in 3-deoxyglucosone levels in diabetic rat plasma.

J Biol Chem 1994; 269: 20275–80.

15.

Niwa

, Miyazaki

, Momoi

, Ogawa

, Maeda

3-Deoxyglucosone, a reactive intermediate of Maillard reaction, accumulating in uremic serum modifies β₂-microglobulin with advanced glycation end-products (Abstract).

J Am Soc Nephrol 1995; 6: 554.

16.

Vlassara

, Bucala

, Striker

Pathogenic effects of advanced glycosylation: Biochemical, biologic, clinical implications for diabetes and aging.

Lab Invest 1994; 70: 138–51.

17.

Vlassara

Recent progress on the biologic and clinical significance of advanced glycosylation end-products.

J Lab Clin Med 1994; 124: 19–30.

18.

Makita

, Bucala

, Rayfield

E.J.

, Friedman

E.A.

, Kaufman

A.M.

, Korbet

S.M.

Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure.

Lancet 1994; 343: 1519–22.

19.

Vlassara

Serum advanced glycosylation end-products: A new class of uremic toxins?

Blood Purif 1994; 12: 54–9.

20.

Kennedy

, Baynes

J.W.

Non-enzymatic glycosylation and the chronic complications of diabetes. An overview.

Diabetologia 1984; 26: 93–8.

21.

Brownlee

, Cerami

, Vlassara

Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular diseases.

Diabetes Metab Rev 1988; 4: 437–51.

22.

Dobbie

J.W.

Advanced glycosylation end products in peritoneal tissue with different solutions.

Perit Dial Int 1997; 17(Suppl 2): S27–30.

23.

Moore

H.L.

A chronic catheter model for PD exchanges in the ambulatory rat (Abstract).

Perit Dial Int 1992; 12(Suppl 1): S141.

24.

Lamb

, Cattell

W.R.

, Dawnay

Glycated albumin in serum and dialysate of patients on continuous ambulatory peritoneal dialysis.

Clin Sci 1993; 84: 619–26.

25.

Dawney

Advanced glycation end products in peritoneal dialysis.

Perit Dial Int 1996; 16(Suppl 1): S50–3.

26.

Millar

D.J.

, Dawnay

A.B.S.

Glycation of albumin with icodextrin (Abstract).

J Am Soc Nephrol 1995; 6: 551.

27.

Struijk

D.G.

, Krediet

R.T.

, Koomen

G.C.M.

, Hoek

F.J.

, Boeschoten

E.W.

, Reijden

H.J.

Functional characteristics of the peritoneal membrane in long-term continuous ambulatory peritoneal dialysis.

Nephron 1991; 59: 213–20.

28.

Tooke

J.E.

Microcirculation and diabetes.

Br Med Bull 1989; 45: 206–23.

29.

Rippe

Pathophysiological description of the ultra-structural changes of the peritoneal membrane during long-term continuous ambulatory peritoneal dialysis.

Blood Purif 1994; 12: 211–20.

30.

Tsilibary

E.C.

, Charonis

A.S.

, Reger

L.A.

, Wohlhueter

R.M.

, Furcht

L.T.

The effect of nonenzymatic glycosylation on the binding of the main noncollagenous NC1 domain to type IV collagen.

J Biol Chem 1988; 263: 4302–8.

31.

Charonis

A.S.

, Reger

L.A.

, Dege

J.E.

, Kouzi–Koliakos

, Furcht

L.T.

, Wohlhueter

R.M.

Laminin alterations after in vitro nonenzymatic glycosylation.

Diabetes 1990; 39: 807–14.

32.

Esposito

, Gerlach

, Brett

, Stern

, Vlassara

Endothelial receptor–mediated binding of glucose-modified albumin is associated with increased mono-layer permeability and modulation of cell surface coagulant properties.

J Exp Med 1989; 170: 1397–407.

33.

Nakayama

, Kawaguchi

, Yamada

, Hasegawa

, Takazoe

, Katoh

Immunohistochemical detection of advanced glycosylation end products in the peritoneum and its possible pathophysiological role in CAPD.

Kidney Int 1997; 51: 182–6.

34.

Jörres

, Topley

, Gahl

G.M.

Biocompatibility of peritoneal dialysis fluids (Editorial).

Artif Organs 1992; 15: 79–83.

35.

Dobbie

J.W.

Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis.

Perit Dial Int 1992; 12: 14–27.

36.

Frazier–Jessen

M.R.

, Kovacs

E.J.

Abdominal wall thickness as a means of assessing peritoneal fibrosis in mice.

J Immunol Methods 1993; 162: 115–21.